School of Nursing and Rehabilitation, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
Front Endocrinol (Lausanne). 2021 Jul 19;12:598008. doi: 10.3389/fendo.2021.598008. eCollection 2021.
Fibroblast growth factor 21 (FGF21), is an emerging metabolic regulator mediates multiple beneficial effects in the treatment of metabolic disorders and related complications. Recent studies showed that FGF21 acts as an important inhibitor in the onset and progression of cardiovascular complications of diabetes mellitus (DM). Furthermore, evidences discussed so far demonstrate that epigenetic modifications exert a crucial role in the initiation and development of DM-related cardiovascular complications. Thus, epigenetic modifications may involve in the function of FGF21 on DM-induced cardiovascular complications. Therefore, this review mainly interprets and delineates the recent advances of role of FGF21 in DM cardiovascular complications. Then, the possible changes of epigenetics related to the role of FGF21 on DM-induced cardiovascular complications are discussed. Thus, this article not only implies deeper understanding of the pathological mechanism of DM-related cardiovascular complications, but also provides the possible novel therapeutic strategy for DM-induced cardiovascular complications by targeting FGF21 and related epigenetic mechanism.
成纤维细胞生长因子 21（FGF21）是一种新兴的代谢调节剂，可介导代谢紊乱及其相关并发症的多种有益作用。最近的研究表明，FGF21 作为糖尿病（DM）心血管并发症发生和进展的重要抑制剂。此外，到目前为止的证据表明，表观遗传修饰在 DM 相关心血管并发症的发生和发展中发挥着关键作用。因此，表观遗传修饰可能涉及 FGF21 在 DM 诱导的心血管并发症中的功能。因此，本综述主要解释和阐述了 FGF21 在 DM 心血管并发症中的作用的最新进展。然后，讨论了与 FGF21 在 DM 诱导的心血管并发症中的作用相关的表观遗传变化。因此，本文不仅暗示了对 DM 相关心血管并发症病理机制的更深入理解，而且通过靶向 FGF21 和相关的表观遗传机制，为 DM 诱导的心血管并发症提供了可能的新的治疗策略。
